Daniel L. Riggs

Daniel L. Riggs

Auto-generated profile, based on publicly available information

Daniel L. Riggs

Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. Significance: These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM. See related article by Neri, Barwick, et al., p. 56. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4

6 November 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
PNPaola Neri
Paola Neri
BBBenjamin G. Barwick
Benjamin G. Barwick
DJDavid Jung
David Jung
JPJonathan C. Patton
Jonathan C. Patton
RMRanjan Maity
Ranjan Maity
NBNizar J. Bahlis
Nizar J. Bahlis
Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanisms are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted chromatin-bound IKZF1, but eviction of P300 and BRD4 coactivators only occurred in IMiD-sensitive cells. IKZF1-bound enhancers overlapped other transcription factor binding motifs, including ETV4. Chromatin immunoprecipitation sequencing showed that ETV4 bound to the same enhancers as IKZF1, and ETV4 CRISPR/Cas9-mediated ablation resulted in sensitization of IMiD-resistant MM. ETV4 expression is associated with IMiD resistance in cell lines, poor prognosis in patients, and is upregulated at relapse. These data indicate that ETV4 alleviates IKZF1 and IKZF3 dependency in MM by maintaining oncogenic enhancer activity and identify transcriptional plasticity as a previously unrecognized mechanism of IMiD resistance. Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by maintaining MYC and other oncogenes. These data implicate transcription factor redundancy as a previously unrecognized mode of IMiD resistance in MM. See related article by Welsh, Barwick, et al., p. 34. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4

15 September 2013 in Journal of Signal Transduction
Verified
Journal Article
Open access
PDF file
JLJoseph C Loftus
Joseph C Loftus
ZYZhongbo Yang
Zhongbo Yang
JKJean Kloss
Jean Kloss
HDHarshil Dhruv
Harshil Dhruv
NTNhan L. Tran
Nhan L. Tran
DRDaniel L. Riggs
Daniel L. Riggs
Glioma cell migration correlates with Pyk2 activity, but the intrinsic mechanism that regulates the activity of Pyk2 is not fully understood. Previous studies have supported a role for the N-terminal FERM domain in the regulation of Pyk2 activity as mutations in the FERM domain inhibit Pyk2 phosphorylation. To search for novel protein-protein interactions mediated by the Pyk2 FERM domain, we utilized a yeast two-hybrid genetic selection to identify the mammalian Ste20 homolog MAP4K4 as a binding partner for the Pyk2 FERM domain. MAP4K4 coimmunoprecipitated with Pyk2 and was a substrate for Pyk2 but did not coimmunoprecipitate with the closely related focal adhesion kinase FAK. Knockdown of MAP4K4 expression inhibited glioma cell migration and effectively blocked Pyk2 stimulation of glioma cell. Increased expression of MAP4K4 stimulated glioma cell migration; however, this stimulation was blocked by knockdown of Pyk2 expression. These data support that the interaction of MAP4K4 and Pyk2 is integrated with glioma cell migration and suggest that inhibition of this interaction may represent a potential therapeutic strategy to limit glioblastoma tumor dispersion.

25 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Differentially expressed genes between POM (200 nM), GNE781 (40nM) or both (Combo) in JJN3 and KMS11 control (eGFP) and BATF overexpressing cells

25 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Differentially expressed genes between POM (200 nM), GNE781 (40nM) or both (Combo) in JJN3 and KMS11 control (eGFP) and BATF overexpressing cells

8 January 2024
Verified
Other
Open access
PNPaola Neri
Paola Neri
BBBenjamin G. Barwick
Benjamin G. Barwick
DJDavid Jung
David Jung
JPJonathan C. Patton
Jonathan C. Patton
RMRanjan Maity
Ranjan Maity
NBNizar J. Bahlis
Nizar J. Bahlis
Genes whose expression are associated with ETV4 in NDMM and in RRMM patients enrolled in the CoMMpass study.